10 Feb 2011: NorDiag and PSS, a leading global provider of laboratory instruments for nucleic acid extraction, have entered into an agreement regarding development of reagents for next generation sequencers and protocols for SX-8G Compact. NorDiag shall develop reagents and protocols  which will be applied to PSS' instruments.

"The agreement confirms NorDiag's unique competence in reagents- and software development for sample preparation," comments CEO Mårten Wigstøl.
PSS is listed on JASDAQ with ticker 7707.

Complete stock exchange release from PSS is attached.
 
Contact: CEO Mårten Wigstøl               Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information - www.nordiag.com.

Read the press release from PSS here

Read the notice in Norwegian here